ADAGIO THERAPEUTICS Funding & Investors
Waltham, MA
Adagio Therapeutics is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses. They believe that antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. Their candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Their portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape.
adagiotx.comTotal Amount Raised: $553,500,032
ADAGIO THERAPEUTICS's Investors
ADAGIO THERAPEUTICS Funding Rounds
Post Ipo Equity
$57,500,000
Post Ipo Debt
$30,000,000
Post Ipo Debt Investors
First Citizens BankSeries C
$336,000,000
Series C Investors
RA Capital ManagementPremji InvestArrowMark Colorado HoldingsForesite CapitalRedmile GroupOmega Fund ManagementPolaris PartnersFidelityGVMithril Capital ManagementAdimabPopulation Health PartnersOrbiMed AdvisorsFederated InvestorsIPO
Unknown
Series B
$80,000,000
Series B Investors
GVMithril Capital ManagementFidelityOrbiMed AdvisorsPolaris PartnersOmega Fund ManagementPopulation Health PartnersSeries A
$50,000,000
Series A Investors
Mithril Capital ManagementPolaris PartnersAdimabOrbiMed AdvisorsFidelityGVM28 Capital